Plexin domain-containing 1 may be a biomarker of poor prognosis in hepatocellular carcinoma patients, may mediate immune evasion

Figure 5 Risk model incorporating plexin domain-containing 1-associated immune checkpoints in hepatocellular carcinoma based on the The Cancer Genome Atlas database. A: Construction of a prognostic immune checkpoint model associated with plexin domain-containing 1 (PLXDC1) in hepatocellular carcinoma (HCC); B and C: Proportional regression model of Cox risk for PLXDC1 in HCC with associated immune checkpoints CD73, TNFRSF4, and TNFSF4; D and E: Univariate and multifactor Cox analysis of model risk scores combined with clinical factors; F: Prognostic analysis results; G: The accuracy of the Cox model risk prediction was assessed using receiver operational characteristic curves; H: The immune evasion ability and immunotherapy response were assessed in the high-risk and low-risk groups; the high-risk group had a better treatment outcome than the low-risk group. ^aP < 0.05; ^bP < 0.01; ^cP < 0.001. PLXDC1: Plexin domain-containing 1.